Bioventix plc
("Bioventix" or the "Company")
Holdings in Company
Bioventix plc (AIM: BVXP) was notified on 16 April 2015 that Adrian Williams
now has a total beneficial holding of 245,172* ordinary shares of 5 pence each
("Ordinary Shares") in the Company. This represents approximately 4.85% of the
Company's issued share capital.
* Of the total holding, 237,534 are held in his own name, with the balance of
7,638 being held by DM plc, of which Mr Williams is the ultimate controlling
party.
For further information please contact:
Bioventix plc Chief Executive Officer Tel: 01252 728 001
Peter Harrison
finnCap Ltd Corporate Finance Tel: 020 7220 0500
Geoff Nash/Simon Hicks Corporate Broking
Steve Norcross
About Bioventix plc:
Bioventix (www.bioventix.com) specialises in the development and commercial
supply of high-affinity monoclonal antibodies with a primary focus on their
application in clinical diagnostics, such as in automated immunoassays used in
blood testing. The antibodies created at Bioventix are generated in sheep and
are of particular benefit where the target is present at low concentration and
where conventional monoclonal or polyclonal antibodies have failed to produce a
suitable reagent. Bioventix currently offers a portfolio of antibodies to
customers for both commercial use and R&D purposes, for the diagnosis or
monitoring of a broad range of conditions, including heart disease, cancer,
fertility, thyroid function and drug abuse. Bioventix currently supplies
antibody products and services to the majority of multinational clinical
diagnostics companies. Bioventix is based in Farnham, UK and its shares are
traded on AIM under the symbol BVXP.© 2015 PR Newswire
